LAB STANDARD BIOTOOLS INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1162194 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-2.2%
TTM net income YoY203.8%
TTM EPS YoY203.0%
Revenue 3-yr CAGR-7.1%
Net income 3-yr CAGR—
Margins
Gross margin52.2%
Operating margin-97.5%
Net margin157.6%
FCF margin-77.8%
EBITDA margin-91.3%
Returns
ROE27.9%
ROA22.7%
ROIC (approx.)-23.4%
Asset turnover0.14x
Leverage & solvency
Liabilities / assets12.5%
Debt / equity0.00x
Current ratio9.75x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.48x
Accruals ratio33.6%
Payout ratio—
Capex / revenue1.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $85.33M | $91.01M | $106.34M | $97.95M | $130.58M |
| Cost of revenue | $42.79M | $46.12M | $55.89M | $60.90M | — |
| Gross profit | $42.54M | $44.88M | $50.45M | $37.05M | — |
| R&D expense | $25.99M | $28.83M | $25.95M | $37.38M | $37.94M |
| SG&A expense | $109.86M | $103.06M | $87.54M | $102.28M | $98.89M |
| Operating income | -$110.25M | -$127.48M | -$76.60M | -$116.20M | -$67.46M |
| Interest expense | — | — | $4.57M | $4.33M | $3.82M |
| Pretax income | -$96.70M | -$90.40M | -$74.20M | -$192.93M | -$63.66M |
| Income tax | -$37.88M | $542,000 | $452,000 | -$2.83M | -$4.42M |
| Net income | -$74.90M | -$138.88M | -$74.66M | -$190.10M | -$59.24M |
| EBITDA | -$100.99M | -$114.97M | -$72.62M | -$113.41M | -$64.24M |
| EPS (basic) | -0.20 | -0.52 | -0.94 | -2.43 | -0.78 |
| EPS (diluted) | -0.20 | -0.52 | -0.94 | -2.43 | -0.78 |
| Weighted avg. shares (diluted) | 381.62M | 353.25M | 79.16M | 78.31M | 75.79M |
| Balance sheet | |||||
| Cash & equivalents | $120.86M | $168.82M | $52.50M | $82.32M | $29.47M |
| Short-term investments | $66.71M | $126.15M | $63.19M | $84.47M | $0 |
| Receivables | $13.43M | $14.74M | $19.66M | $17.28M | $18.32M |
| Inventory | $19.98M | $20.74M | $20.74M | $21.47M | $20.82M |
| Current assets | $454.26M | $375.88M | $158.22M | $208.81M | $72.07M |
| PP&E, net | $19.27M | $22.77M | $24.19M | $25.65M | $28.03M |
| Goodwill | — | $111.30M | $106.32M | $106.25M | $106.38M |
| Intangibles | — | $28.95M | $1.40M | $12.60M | $27.93M |
| Total assets | $567.75M | $612.35M | $323.07M | $390.31M | $275.21M |
| Current liabilities | $108.31M | $65.89M | $109.33M | $43.44M | $49.57M |
| Long-term debt | — | $299,000 | $63.51M | $64.89M | — |
| Total debt | — | $299,000 | $63.51M | $64.89M | — |
| Total liabilities | $143.46M | $140.62M | $159.87M | $160.52M | $180.62M |
| Shareholders' equity | $424.29M | $471.72M | -$148.05M | -$81.47M | $94.60M |
| Net debt | — | -$168.52M | $11.01M | -$17.43M | — |
| Shares outstanding | 386.38M | 377.53M | 80.23M | 79.48M | 76.92M |
| Cash flow statement | |||||
| Operating cash flow | -$74.34M | -$143.45M | -$43.29M | -$89.37M | -$44.06M |
| Capital expenditure | $8.30M | $8.36M | $2.83M | $3.83M | $13.26M |
| Free cash flow | -$82.65M | -$151.81M | -$46.12M | -$93.19M | -$57.33M |
| Investing cash flow | $27.41M | $363.17M | $20.24M | -$88.13M | -$11.95M |
| Financing cash flow | $570,000 | -$102.62M | -$6.81M | $230.76M | $15.96M |
| Depreciation & amortization | $9.26M | $12.52M | $3.98M | $2.80M | $3.22M |
| Stock-based compensation | $29.61M | $31.73M | $13.12M | $14.88M | $16.10M |
| Share buybacks | $0 | $40.49M | $5.41M | $563,000 | $0 |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.